Business Context and Reporting Period
Aquestive Therapeutics, Inc. filed this Form 8-K on November 2, 2018, with a report date of November 6, 2018. The filing serves as a current report to disclose significant corporate events, specifically the receipt of FDA approval for a new product and the announcement of third-quarter financial results.
Key Financial Metrics
This filing references the Company's financial results for the third quarter ended September 30, 2018, which are detailed in a press release attached as Exhibit 99.1. The text of this 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Investors must refer to the attached Exhibit 99.1 for these figures.
Material Changes and Events
- FDA Approval: On November 2, 2018, the U.S. Food and Drug Administration (FDA) approved Sympazan® (clobazam) Oral Film (OF).
- Indication: The approval is for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients 2 years of age or older.
- Financial Announcement: The Company announced its Q3 2018 financial results on November 6, 2018, though specific performance metrics are not listed in this summary document.
Guidance, Outlook, and Risks
The filing does not contain specific forward-looking guidance, management commentary on future financial performance, or a detailed discussion of risks and contingencies within the body text. The document notes that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q3 2018 revenue, net loss, and cash position figures.
- Verify the commercial launch timeline and pricing strategy for Sympazan® following FDA approval.
- Assess the potential market size for Lennox-Gastaut Syndrome (LGS) treatments in the 2+ age demographic.
- Confirm the Company's cash runway and capital requirements post-approval.